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a b s t r a c t
APOBEC3G (A3G) is a host-expressed protein that inactivates retroviruses through the mutagenic
deamination of cytosines (C) to uracils (U) in single-stranded DNA (ssDNA) replication products. A3G
prefers to deaminate cytosines preceded by a cytosine (50CC), whereas all other A3 proteins target
cytosines in a 50TC motifs. Structural and mutational studies have mapped the dinucleotide deamination
preference of A3G to residues in loop 7 of the catalytic C-terminal domain of the protein. Here we report
that A3G with a double W94A/W127A substitution in its N-terminus, designed to abolish RNA binding
and protein oligomerization, alters the DNA deamination speciﬁcity of the enzyme from 50CC to 50TC on
proviral DNA. We also show that the double substitution severely impairs its deaminase and
antiretroviral activities on Vif-deﬁcient HIV-1. Our results highlight that the N-terminal domain of the
full length A3G protein has an important inﬂuence on its DNA sequence speciﬁcity and mutator activity.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Retroviruses, such as HIV-1, can insert their genetic material into
the genome of their host within only a few hours after entering a
cell. To avoid damage or modiﬁcations to their genomic DNA,
mammals have evolved several defense mechanisms against these
unique pathogens. Members of the APOBEC3 (A3) family are
deoxycytidine deaminases that present an important barrier to
retroviral replication and spread in mammals (Reviewed in
Desimmie et al., 2014; Harris and Dudley, 2015) There are seven
A3 in humans, A3A to A3H, with each enzyme being characterized
by the presence of one (A3A and A3C) or two (A3B, A3D, A3F and
A3G) zinc (Z)-coordinating domains (Jarmuz et al., 2002; LaRue
et al., 2009). There are three distinct types of Z domains in humans
and primates, each containing a conserved Hx1Ex24–28PCx2–4C motif
that constitutes a putative catalytic site in which the histidine and
cysteines coordinate a zinc ion, whereas the glutamic acid acts as a
proton shuttle. It is the hydrolytic attack of a zinc-activated water
molecule on the C4 amine of the substrate deoxycytidine that
results in the generation of a déoxyuridine (Neuberger et al., 2003).
A3 proteins deaminate exclusively single-stranded DNA (ssDNA)
(Harris et al., 2003; Suspene et al., 2004; Yu et al., 2004). The
minus strand viral cDNA that is synthesized during the reverse
transcription of retroviral genomic RNA is targeted and uracilated
by A3 proteins. Uracils then template the insertion of adenosines
(A) during the synthesis of the plus-strand proviral DNA thereby
giving rise to G-to-A mutations. A high density of mutations, also
called hypermutation, result in the incorporation of premature stop
codons and protein defects that inactivate viral functions (Lecossier
et al., 2003; Mariani et al., 2003).
The deaminase activity of A3 proteins is highly sequence-
speciﬁc. A3G is the only enzyme of the family that strongly prefers
to target cytosines (underlined) immediately preceded by a
cytosine (50CC), whereas all other A3 deaminate cytosines in a
50TC motif (Beale et al., 2004; Dang et al., 2006; Doehle et al.,
2005; Harris et al., 2003; Langlois et al., 2005; Liddament et al.,
2004; OhAinle et al., 2006). Because the crystal structure of the
full-length double-domain A3G protein has not yet been solved,
there is an incomplete understanding of the global residues that
inﬂuence target DNA speciﬁcity. Structurally, all A3 proteins share
several conserved features including at least one Z domain con-
sisting of ﬁve β-sheets surrounded by six α-helices (Bohn et al.,
2013; Byeon et al., 2013; Chen et al., 2008; Kitamura et al., 2012;
Siu et al., 2013). A recent study in which A3A and A3G residues
were interchanged found that replacing D317 of the CTD of A3G,
situated in loop 7 between β4 and α4, with the homologous
tyrosine residue of A3A (Y132) was sufﬁcient to alter the local
dinucleotide preference for deamination from 50CC to 50TC
(Rathore et al., 2013). Those results are supported by previous
reports also implicating loop 7 residues in the dinucleotide
deamination preference of several A3 proteins and also that of
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the activation-induced deaminase (AID) (Carpenter et al., 2010;
Kohli et al., 2009, 2010; Langlois et al., 2005; Wang et al., 2010).
Because of its potent antiretroviral activity against a wide range
of retroviruses, A3G is the best-characterized member of the A3
family. A3G has two Z domains (Z2-Z1) with each one containing a
seemingly intact catalytic site, however only its C-terminal Z1
domain (CTD) is catalytically active (Hache et al., 2005; Navarro
et al., 2005). The N-terminal domain (NTD) of the enzyme has
been ascribed various other functions such as binding to HIV-1 Vif
and virion encapsidation (Huthoff et al., 2009; Huthoff and Malim,
2007; Lavens et al., 2010; Mangeat et al., 2004; Schrofelbauer et al.,
2004). Residues located in the NTD have also been implicated in
nucleic acid binding, especially RNA (Bach et al., 2008; Bélanger
et al., 2013; Bulliard et al., 2009; Huthoff et al., 2009; Iwatani et al.,
2006; Khan et al., 2007; Shindo et al., 2012).
In addition to its cytosine deaminase activity, it is well established
that A3G also has the ability, in certain experimental conditions, to
hinder retroviral infection by means that are independent of deamina-
tion (Bélanger et al., 2013; Bishop et al., 2006, 2008; Guo et al., 2007;
Iwatani et al., 2007; Li et al., 2007; Lu et al., 2015; Luo et al., 2007;
Mariani et al., 2003; Mbisa et al., 2010; Newman et al., 2005; Wang et
al., 2012). In particular, several groups have demonstrated defects in
tRNA3Lysprimer annealing and strand transfers during replication,
which consequently lead to decreased levels of early and late reverse
viral transcript accumulation as well as reduced proviral integration.
Overall, these restriction mechanisms are thought to occur as a result
of the direct interaction of A3G with the viral reverse transcriptase
(RT) and integrase (IN), and possibly also through an alteration in the
processivity of the reverse transcriptase caused by the clamping of
A3G onto its ssDNA substrate during reverse transcription (Bishop et
al., 2008; Luo et al., 2007; Wang et al., 2012). Recent work from our
group has demonstrated that RNA binding by A3G is required for
deamination-independent restriction (Bélanger et al., 2013). We
mapped the RNA-binding ability of A3G to two tryptophans, W94
and W127, in the non-catalytic NTD of the protein. By individually
substituting these two residues to alanine, A3G lost most
deamination-independent functions including the inhibitions of late
reverse transcript accumulation and proviral integration (Bélanger
et al., 2013).
In this report we show that an RNA-binding defective mutant of
A3G with two substitutions in its N-terminus, W94A/W127A, displays
altered DNA substrate speciﬁcity. The loss of RNA-binding did not
prevent the mutant enzyme from being incorporated into retrovirus
virions, however its antiretroviral activity against a Vif-deﬁcient HIV-1
pseudovirus was completely lost. Our observations support that the
ability to bind RNA by full length A3G is required for retrovirus
restriction and for high frequency provirus hypermutation. Surpris-
ingly, the few hypermutated proviral sequences that were recovered
from infected cells displayed a shift in the preferred target motif for
deamination from 50CC to 50TC. This shift in target DNA speciﬁcity of
the enzyme was also independently conﬁrmed in a bacterial mutator
assay where the double mutant was found to be as potent as the wild
type A3G protein. This represents the ﬁrst report to date showing the
involvement of the NTD in the target speciﬁcity and regulation of
A3G's mutator activity on a retrovirus.
Results and discussion
In a previous study we demonstrated that A3G [W94A] and A3G
[W127A] mutants each had a signiﬁcantly reduced ability to bind RNA,
and more speciﬁcally, to 7SL, Alu, hY1 and hY3 RNAs (Bélanger et al.,
2013). However, weak RNA binding could still be detected with these
mutants. Here we were ﬁrst interested to determine whether the
double W94A/W127A substitution could account for all detectable
RNA binding by A3G. Lysates from 293T cells transfected with
Flag-tagged A3G or mutants were used for Co-IP using anti-Flag
conjugated agarose beads followed by RNA isolation. Samples were
then subjected to qPCR to measure the relative binding of each
APOBEC to RNA. In these conditions, [W94A/W127A] did not bind to
any of the RNAs tested above the background level set by the APOBEC2
(A2) negative control (Fig. 1A). A3G has a well-established ability to
assemble into large oligomeric or high molecular mass (HMM)
ribonucleic complexes (Chiu et al., 2005). In a previous report we
showed that the W94A and W127A point mutants displayed a partial
ability to assemble into oligomeric structure compared to wild type
A3G (Bélanger et al., 2013). Here we analyzed the double mutant in
presence and absence of RNase treatment. We could not detect any
evidence of assembly into complexes that are RNA-dependent
(Fig. 1B). Surprisingly, although RNA binding was lost, cytoplasmic
foci believed to be P-bodies, stress granules and other RNA processing
bodies that normally associate with A3Gwere still visible when similar
levels of protein expression were compared (Fig. 1C and D) (Gallois-
Montbrun et al., 2007; Kozak et al., 2006; Wichroski et al., 2006). This
observation thereby indicates that association of A3G with these
structures is not dependent on cellular RNA binding, nor is it
dependent on protein aggregation or self-assembly (Fig. 1E).
We next investigated the impact of the double mutation on
antiretroviral activity. Here we produced HIV [p8.9] pseudoviruses
by co-transfecting viral expression plasmids along with A3G and
various A3G mutants, including the catalytically inactive E259Q
mutant and single point mutants W94A and W127A into 293T cells.
We then conﬁrmed by Western blot analysis that all the mutants,
including [W94A/W127A], were expressed in 293T cells and were also
efﬁciently packaged into virions, as judged by p24 capsid expression
used for normalization (Fig. 2A). For reasons that are yet unclear, A3G
mutants containingW94A orW127A point substitutions or the double
substitution were all efﬁciently packaged into HIV [p8.9] pseudo-
viruses (Fig. 2A), but not into HIV-1 ΔV if viruses as would be expected
(data not shown) (Bélanger et al., 2013). Consistent with our previous
ﬁndings showing that the W94A and W127A point mutants displayed
reduced antiretroviral activities (Bélanger et al., 2013), [W94A/W127A]
was completely unable to restrict the infection of the virus (Fig. 2B).
Loss of the antiretroviral activity of the double mutants could
be the result of protein misfolding causing defective deaminase
activity. To evaluate the mutator activity of A3G [W94A/W127A]
we conducted a bacterial mutator assay in E. coli. An increased
frequency of rifampicin-resistant (RifR) colonies arises when A3G
mutates the rpoB gene of E.coli rendering it resistant to rifampicin
(Harris et al., 2002). Our results show that the full-length double
mutant is well expressed in E. coli and generates similar frequen-
cies of RifR colonies than wild type A3G (Fig. 2C and D) and
(Table 1). Having conﬁrmed that the double mutant's mutator
activity is unaffected, we next investigated whether it could
deaminate proviral DNA. Genomic DNA from 293T cells infected
with viruses produced in presence of A3G and mutant proteins
was isolated after 24 h. The eGFP reporter gene contained within
the provirus was ampliﬁed by PCR and 120 clones were
sequenced. None of the clones displayed G-to-A hypermutation
in presence of the double mutant (data not shown). To determine
whether there was a very low frequency of hypermutated
sequences we next used 3D-PCR and HRM analysis (Bélanger
et al., 2014; Suspene et al., 2005). These methods promote the
selective PCR ampliﬁcation (3D-PCR) or detection (HRM) of hyper-
mutated sequences and provide qualitative information as to the
intensity of the mutations. Results of these assays revealed the
presence of mutations at intensities much lower than wild type
A3G but similar to that of the single mutants (Fig. 2E and F) and
(Table 1). No mutations were detected in the integrated proviral
DNA of viruses produced in presence of A3G E259Q or A2. These
results therefore indicate that the double mutant is capable of
mutating provirus DNA, but at very low frequencies.
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Fig. 1. Binding of A3G [W94A/W127A] to RNA and visualization of its subcellular localization. (A) Flag-A2, Flag-A3G or RNA-binding mutants of A3G were transfected in 293T
cells. 48 h after transfection, cells were harvested, lysed in NP40 lysis buffer and subjected to Co-IP using anti-Flag-conjugated agarose beads. RNA was then isolated from
immunoprecipitates and the binding of the different APOBECs to 7SL, Alu, hY1 and hY3 RNAs was determined by qPCR. Relative binding to A3G is depicted. Results represent
the mean 7SD of triplicate values from three independent transfection experiments. (B) Lysates of transfected 293T cells, treated (right panels) or untreated with RNase A
(left panels), were resolved by non-denaturing 5–40% sucrose gradient velocity ultra-centrifugation and analyzed by Western blot. Protein detection was performed with an
anti-Flag antibody. MDT, monomers, dimers and tetramer; LMM, low molecular mass; HMM, high molecular mass. (C) eGFP-A3G and eGFP-A3G [W94A/W127A] expression
plasmids were transfected in 293T cells and cultured in DMEM without phenol red for 48 h. Fluorescent images of the subcellular localization of the proteins were acquired
with a 63X objective. (D) Cells transfected with eGFP-A3G or eGFP-A3G [W94A/W127A] were lysed 48 h after transfection and analyzed by Western blot using an anti-eGFP
antibody; β-Tubulin was used as a loading control. (E) 293T cells were singly transfected (lanes 1, 2, 4 and 5) or co-transfected (lanes 3, 6 and7) with Flag- or eGFP-tagged
APOBEC3 proteins. Pull-downs were carried out with anti-GFP magnetic beads. Homodimers were detected with an anti-Flag antibody (lanes 7–8).
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We next analyzed the local DNA sequence context of the
mutations in hypermutated proviral clones obtained by 3D-PCR.
Our analysis revealed that the preferred dinucleotide DNA target
site for A3G [W94A/W127A] had changed from 50CC to a very ﬁrm
50TC context (Table 2). We also observed a change in DNA
deamination speciﬁcity at position -1 in a segment of the rpoB
gene isolated from RifR E. coli colonies from a dominant 50CC to
50KC (where K is A or G) (Table 2 and Fig. 3) (Beale et al., 2004;
Harris et al., 2003). Such a shift in deamination speciﬁcity to favor
50TC is likely to further contribute to the low viral gene-
inactivating potential of the mutant enzyme. An important part
of the gene inactivation potency of A3G relies on the generation of
TAG termination codons caused by deamination opposite to TGG
tryptophan codons (Armitage et al., 2012). Weak mutational
activity and frequency of mutated proviral DNA sequences com-
bined to a 50TC deaminase speciﬁcity would altogether highly
compromise the antiretroviral activity of the A3G [W94A/W127A]
protein.
Fig. 2. A3G [W94A/W127A] hypermutates proviral DNA at a low frequency. (A) HIV [p8.9] viral particles produced in the presence of A3G or mutants of A3G were puriﬁed
from cell supernatants, lysed and assayed for protein levels by Western blot analysis. Lysates of virus-producer cells are also presented. (B) Restriction of HIV [p8.9] infection
by A3G and mutants as measured by ﬂow cytometry in 293T target cells 24 h after infection. Results represent the mean 7SD of triplicate values from three independent
transfection experiments. N.S., not signiﬁcant. (C) Comparison of the mutator activities of A3G and A3G [W94A/W127A] in E. coli. Each point represents in Log the mutation
frequency (RifR mutants per 107 viable cells) of an independent culture; the median values are indicated by a bar. Statistical signiﬁcance was calculated using a two-tailed
Student's t-test. (D) Western blot analysis performed on lysates of IPTG-induced bacterial cells used in the mutator assay described above. The expression of Kat-α was used
as a loading control. (E and F) HIV [p8.9] viral particles produced in the presence of APOBEC proteins were used to infect 293T target cells. gDNA was extracted from infected
cells 24 h after infection and used for (E) HRM analysis or (F) 3D-PCR analysis. (E) Duplicate melting curves for one representative experiment of three is shown. A2-treated
samples (blue) delineate to the right a shaded region containing non-hypermutated sequences. PCR amplicons enriched in A/T content due to DNA deamination induce a
shift in their melt curves towards lower temperatures. The linear segment of the melt-point threshold of the curve is presented for clarity. (F) 3D-PCR analyses. One
representative experiment of three is shown. Ampliﬁcation at lower temperatures is indicative of increased G-to-A hypermutation intensity.
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Overall, our results suggest that tryptophan to alanine sub-
stitutions at positions 94 and 127 of the NTD may affect the overall
DNA substrate binding efﬁciency of the full length A3G protein. In
fact, several published reports have speculated that W94 and
W127 may interact with ssDNA substrates; residue W94 has been
recently proposed to contact the DNA substrate in a full-length
model of A3G (Lu et al., 2015), and moreover, the residue homo-
logous to W94 in A3A (W98) has been shown to be directly
involved in DNA binding (Logue et al., 2014). Furthermore, Chen
et al. (2008) previously identiﬁed W285, which is homologous to
W94 in the CTD of A3G, as an important contributor to DNA-
binding. Substrate interactions with residues within the NTD could
contribute to its positioning and stabilization for efﬁcient deami-
nation by the active site of the CTD. Finally, the W127A substitu-
tion has been shown to alter the scanning mechanism of the
protein on ssDNA causing a decreased mutagenic potential, pre-
sumably because of the loss of protein homodimerization (Ara et
al., 2014). Our experimental data therefore supports these studies
by implicating both W94 and W127 in not only RNA binding, but
also in physical interactions with the ssDNA substrate.
To date, the DNA dinucleotide preference of A3G has been
attributed mainly to amino acids comprising loop 7 of the CTD of
the protein. More speciﬁcally, Rathore et al. identiﬁed that residue
D317 is responsible for α-helix capping resulting in restrained mobility
of loop 7 and the generation of a binding pocket more favorable for
the inclusion of cytosine than any other base (Rathore et al., 2013). In
addition, according to the “brim model” for DNA binding, the initial
engagement of the substrate has been proposed to occur via the NTD
of A3G followed by a prolonged binding by the CTD that then carries
out the deamination (Shindo et al., 2012). Because W127 is also
located in loop 7 of the NTD of A3G, it is possible that mutations at
positions 94 and 127 could destabilize the initial DNA substrate
binding resulting in a less stringent substrate selection by the catalytic
CTD. The crystal structure of full-length A3G bound to its ssDNA
substrate would certainly help better understand this process.
Another factor that may also contribute to the loss of anti-
retroviral activity of the [W94A/W127A] mutant is the lack of
deamination-independent restriction. We previously reported that
both the W94A and W127A point mutants did not exhibit the
typical features of deamination-independent restriction such as
reduced late-reverse transcript accumulation and proviral integra-
tion (Bélanger et al., 2013). Although the same loss-of-function is
expected of the double mutant, an antiretroviral feature that was
not investigated is binding to the viral IN and RT. Interactions of
A3G with these two viral proteins have previously been linked to
reduced retroviral infection (Luo et al., 2007; Wang et al., 2012).
In order to address this question, HIV [p8.9] pseudoviruses were
produced in the presence or absence of Flag-tagged APOBEC
proteins followed by co-immunoprecipitation (co-IP) using anti-
Flag-conjugated agarose beads. Viral proteins were detected in
immunoprecipitates by Western blotting. Our results show an
interaction between all the A3G mutants, including the double
mutant, with both the viral RT and IN suggesting that the binding
to the viral enzymes does not require RNA (Fig. 4A). Although
[W94A/W127A] was not expressed as well as the point mutants or
the wild type protein in presence of virus, the binding ratios to
either RT or IN were comparable for all A3G proteins (Fig. 4B). We
therefore ﬁnd no evidence that the binding to IN or RT is sufﬁcient
to impede the efﬁciency of viral infection. However, these results
may also indicate that interactions with IN and RT need to occur in
conjunction to RNA or ssDNA binding by the NTD in order for A3G to
exhibit deamination-independent restriction of retroviral infection.
Materials and methods
Antibodies and cells
Human embryonic kidney epithelium (HEK) 293T cells were
cultured in HyClone DMEM/High Glucose medium (Thermo Fischer
Table 1
Mutation analysis in the eGFP gene of HIV [p8.9] and in the rpoB gene of E. coli.
APOBEC3 Sequences
analyzed
Base pairs
analyseda
G-to-A
mutations
C-to-T
mutations
eGFP rpoB eGFP rpoB eGFP rpoB eGFP rpoB
A3G 5 33 1350 6534 29 2 0 28
A3G [W94A/W127A] 10 53 2700 10494 88 11 0 32
a The fragment analyzed in eGFP was 279 bp long whereas the rpoB fragment
length was 198 bp.
Table 2
Local sequence preference for DNA deamination.
APOBEC3 HIV [p8.9] rpoB
2 1 0 2 1 0
A3G
A 24 – – – 3 –
C 38 76 100 87 67 100
T 24 24 – 3 23 –
G 14 – – 10 7 –
A3G [W94A/W127A]
A 24 2 – 3 16 –
C 26 6 100 67 12 100
T 26 92 – 16 42 –
G 24 – – 14 30 –
Values represent the percentage of occurrence of each base at positions 1 and 2
respective to the deaminated cytidine (position 0). Sequence analysis with the A3G
[E259Q] mutant did not yield any mutated sequences. The number of G-to-A/C-to-T
mutations analyzed are as follows: HIV [p8.9]þA3G, n¼29; HIV [p8.9]þA3G
[W94A/W127A], n¼88; rpoBþA3G, n¼30; rpoBþA3G [W94A/W127A], n¼43.
Fig. 3. Distribution of mutations in the rpoB gene of RifR E. coli expressing A3G or
A3G [W94A/W127A]. RifR colonies generated by transforming E.coli with (A) GST-
A3G or (B) GST-A3G [W94A/W127A] expression plasmids were randomly selected
and their rpoB gene was ampliﬁed by PCR. Amplicons were then cloned and sent
for sequencing. Mutated cytosines on the coding strand DNA are indicated in red
and in green are mutated guanines; n indicates the total number of mutations in
each library. Additional sequence information is presented in Table 1.
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Scientiﬁc) supplemented with 10% fetal bovine serum (FBS), 100U/ml
penicillin and 100 μg/ml streptomycin (Multicell). The following
antibodies were used for this study: HRP-conjugated anti-Flag
(A8592, Sigma), anti-eGFP (no.632381, Clontech), anti-p24 (ab9069,
Abcam) and HRP-conjugated anti-β-tubulin (ab21058,Abcam). The
anti-Katα was provided by Dr. Stinzi from the University of Ottawa.
The anti-HIV-1 integrase polyclonal and anti-HIV-1 reverse tran-
scriptase polyclonal antibodies were obtained from the NIH AIDS
Research Reference and Reagent Program (#757 and #6195 respec-
tively) (Grandgenett and Goodarzi, 1994; Szilvay et al., 1992).
Plasmids
Flag-tagged and eGFP-tagged A3G and A2 expression plasmids
were constructed previously (Langlois et al., 2005). Mutants of
A3G were generated from the corresponding plasmids by PCR-
based site directed mutagenesis as previously described (Bélanger
et al., 2013).
The single-cycle HIV[p8.9] reporter pseudovirus has been
described in previous reports (Bélanger et al., 2013; Langlois et al.,
2005). Particles are produced by co-transfecting a Vif-deﬁcient HIV-1
Gag-Pol expression plasmid (p8.9), a packageable HIV-1 LTR
backbone containing the eGFP reporter gene under the control of
an internal SFFV promoter (pCSGW), and a VSV-G expression vector
(pMDG). For the bacterial pGST-expression plasmids, the coding
sequences of A3G and A3G [W94A/W127A] were ampliﬁed by PCR
from pFlag-APOBEC plasmids using the following primers; Xho1-
FWD: 50-GAATTCCCTCGAGGCCACCATGAAGCCTCACTTCAGAAAC-30
and Pst1-REV: 50-CGTCGACTGCAGTCAGTTTTCCTGATTCTGGA-30. The
PCR products were then digested and inserted in the pGST-2 vector
(Addgene) using the Xho1 and Pst1 restriction sites.
Transfections and viral infectivity assays
Transfections and infections were conducted as described
elsewhere (Bélanger et al., 2013). The packaging of APOBEC
proteins inside viral particles was assayed by producing HIV
[p8.9] viruses in the presence of eGFP-tagged APOBECs for 96 h.
Virus-containing supernatants were then puriﬁed by ultra-
centrifugation and pellets were resuspended in RIPA lysis buffer
for Western blot analysis.
Velocity sedimentation
Velocity sedimentation analyses were conducted following the
methods described in a previous report (Bélanger et al., 2013).
Brieﬂy, 293T cells expressing Flag-A2, Flag-A3G or Flag-A3G
[W94A/W127A] were lysed for 30 min on ice with NP40 lysis
buffer supplemented with a protease inhibitor cocktail (Roche).
Half of each sample was then treated for 15 min at room
temperature with 1 mg/mL of RNase A, and both treated and
untreated samples were then loaded onto a 5–40% sucrose step
gradient and resolved by ultra-centrifugation.
Fluorescence microscopy
Detailed procedures for this part can be found in (Bélanger
et al., 2013). 293T cells were seeded in 35 mm glass bottom dishes
(MatTech) and transfected with plasmids expressing eGFP-A3G or
eGFP-A3G [W94A/W127A]. Images of live cells were captured
using a Zeiss Axio Observer.Z1 inverted ﬂuorescent microscope
and a Plan-Apochromat 63x/1.4 oil immersion objective. Acquisi-
tion and deconvolution were performed using the AxioVision
software (Zeiss).
RifR bacterial mutator assay
Bacterial mutator assays were performed as previously
described (Bélanger et al., 2013). In brief, the E. coli uracil
excision-defective strain BW310 was transformed with an empty
pGST or an APOBEC-expressing pGST plasmid and plated overnight
on ampicillin-containing plates. Single transformants were picked
and used to inoculate 6 independent liquid media cultures
supplemented with 1 mM IPTG and 100 μg/mL ampicillin. To
obtain rifampicin resistant (RifR) mutants, 300 μL of each culture
was spread onto low salt LB media containing 100 μg/mL ampi-
cillin and 50 ug/mL rifampicin and incubated at 37 1C overnight.
For sequencing analysis, RifR colonies produced in presence of
A3G or A3G [W94A/W127A] were diluted in 200 ml of water and 2 ml
of the dilution was used in a PCR reaction mix with primers against
a 198 bp region of the RNA polymerase B (rpoB) gene. PCR
ampliﬁcation was carried out by the PrimeStar HS high ﬁdelity
polymerase (Takara Bio Inc.). The sequence of the primers used for
the ampliﬁcations are as follows: rpoB-FWD: 50-TTGGCGAAATGGCG-
GAAAACC-30; rpoB-REV: 50-CACCGACGGATACCACCTGCTG-30. Cycling
conditions were: 94 1C for 2 min, 94 1C for 30 sec, 65 1C for 1 min
and 72 1C for 6 min. Steps 2 to 4 were repeated 8 times with a
decrease of 1 1C in the annealing temperature (step 3) at every
Fig. 4. Interaction of A3G and mutants with HIV-1 RT and IN. (A) HIV [p8.9]
particles were produced in the presence of Flag-A3G or mutants of A3G by co-
transfection in 293T cells. Cells were harvested 48 h after transfection and lysed for
30 min. Lysates were subjected to Co-IP analysis using anti-Flag-conjugated agarose
beads. Following high-pH elution of the proteins from the agarose beads, pre-
cipitates were analyzed by Western blot and probed with anti-Flag, anti-IN and
anti-RT antibodies. The amount of input cell lysate was normalized using β-tubulin
expression. One representative Co-IP experiment of two is depicted.
(B) Quantiﬁcation of Western blot band intensities. Data is presented as the
intensity ratio of the viral proteins (RT or IN) to the speciﬁc A3 proteins in each
experimental condition. Ratios were calculated from the average band intensities
from two independent Co-IP experiments.
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successive cycle. That was followed by 21 cycles at 94 1C for 30 sec,
56 1C for 1 min and 72 1C for 5 min. PCR products were puriﬁed and
sent for Sanger sequencing.
Immunoprecipitation
Methods for immunoprecipitation have been described in
(Bélanger et al., 2013). Brieﬂy, lysates of 293T cells transfected or
co-transfected with Flag-APOBEC and HIV [p8.9] expression vec-
tors were incubated for 3 h at 4 1C with anti-Flag conjugated
agarose beads pre-treated with salmon sperm DNA (500 μg/ml).
Bound complexes were then eluted from the beads with a high-pH
buffer prior to RNA isolation or Western blot analysis.
RNA binding assay
Methods for RNA ampliﬁcation and quantiﬁcation were per-
formed as described in previous reports (Bach et al., 2008;
Bélanger et al., 2013). Brieﬂy, RNA was puriﬁed from normalized
quantities of Flag-tagged APOBEC immunoprecipitates using Trizol
(Sigma). After DNAse treatment of the samples, RNA was reverse-
transcribed using random hexamers and the ImProm-IITM reverse
transcriptase according to the manufacturer's recommendations
(Promega). The resulting cDNA was used for qPCR using GoTaq-
Green Master Mix (Promega) and speciﬁc primers for 7SL, Alu,
hY1, hY3 were used as previously described (Bach et al., 2008;
Bélanger et al., 2013).
3D-PCR
This procedure is detailed in (Suspene et al. (2005)). Infected
293T cells were collected 24 h after infection for gDNA extraction
and 3D-PCR was performed in a two-step protocol using the
PrimeStar HS high ﬁdelity polymerase (Takara Bio Inc.). A ﬁrst-
round PCR was performed to amplify a 717 bp eGFP amplicon
using primers eGFP-FWD: 50-GTGAGCAAGGGCGAGGAGCTGTTC-30
and eGFP-REV:50CTTGTACAGCTCGTCCATGCCGAGA-30. A second-
round 7-point gradient PCR targeting a 279 bp nested fragment
within the eGFP sequence was then performed using primers
R279-FWD: 50–ACAACAGCCACAACGTCTATATCAT-30 and 279-REV:
50–CGTCCATGCCGAGAGTGAT-30. The band of the gradient amplify-
ing at the lowest temperature was then puriﬁed and cloned in the
pBlueScript vector (Agilent Technologies). Independent clones
were sequenced using M13 reverse primers and mutations com-
puted on the plus-strand DNA.
HRM analysis
This method was detailed in a previous report by our group
(Bélanger et al., 2014). The protocol was performed on 20 ng of
gDNA isolated from virus-infected cells. A 717 bp eGFP amplicon
was produced using the MeltDoctor Master Mix (Life Technolo-
gies) and the following primers: eGFP-FWD and eGFP-REV. qPCR
and HRM were carried out on a ViiA™ 7 real-time PCR instrument
(Applied Biosystems), and data was analyzed using the ViiA™
7 system software (Applied Biosystems).
Protein self-association analysis
Pull-downs for eGFP epitope tags were performed according to
the manufacturer's speciﬁcations detailed in the uMACSTM Epitope
Tag Protein Isolation kits (Miltenyi Biotec).
Statistical analysis and software
All statistical analyses were performed using Student's paired t-
test using GraphPad Prism software as previously described
(Bélanger et al., 2013). Western blot band intensity analysis was
performed using ImageJ.
Conclusions
Here we have demonstrated that A3G residues W94 and W127
together account for all detectable RNA binding by the protein. The
dual substitution of these tryptophans to alanines resulted in a
complete loss of retroviral restriction and in a very low frequency of
hypermutated retroviral sequences recovered from infected target
cells. Integrated proviral DNA sequences that were deaminated by
the W94A/W127A mutant displayed a shift in preferred target sites
from 50CC to 50TC. Reduced frequencies of hypermutated proviral
sequences are not a reﬂection of reduced mutator activity by the
A3G double mutant. Mutation assays in bacteria revealed that A3G
[W94A/W127A] was as efﬁcient as the wild type A3G protein,
however with a sequence speciﬁcity that had also changed, but this
time from 50CC to 50KC. These results highlight the essential role
played by these RNA-binding residues in the efﬁcient restriction and
hypermutation of retroviruses. Detailed structural studies have only
focused on the crystal of the CTD of A3G. As a consequence, there is
still a very limited understanding of how the NTD interacts with
both the ssDNA substrate and with the CTD active site of the
enzyme. This study is the ﬁrst to highlight the involvement of the
NTD of A3G in inﬂuencing both the enzyme's substrate speciﬁcity
and mutator activity on retroviral DNA.
Acknowledgments
The authors thank Tyler Renner for helpful discussions, and
Kristin Kemmerich for comments on the manuscript. We are
grateful to the NIH AIDS Research and Reference Reagent Program
for reagents. K.B. holds an Ontario Graduate Scholarship and a
scholarship from le Fonds de Recherche en Santé du Québec. M.-A.
L. holds a Canada Research Chair in Molecular Virology and
Intrinsic Immunity. This research was supported by grant #89774
from the Canadian Institutes of Health Research, and an Early
Researcher Award from the Ontario Ministry of Research and
Innovation to M.-A.L.
References
Ara, A., Love, R.P., Chelico, L., 2014. Different mutagenic potential of HIV-1
restriction factors APOBEC3G and APOBEC3F is determined by distinct single-
stranded DNA scanning mechanisms. PLoS Pathog. 10, e1004024.
Armitage, A.E., Deforche, K., Chang, C.H., Wee, E., Kramer, B., Welch, J.J., Gerstoft, J.,
Fugger, L., McMichael, A., Rambaut, A., Iversen, A.K., 2012. APOBEC3G-induced
hypermutation of human immunodeﬁciency virus type-1 is typically a discrete
“all or nothing” phenomenon. PLoS Genet. 8, e1002550.
Bach, D., Peddi, S., Mangeat, B., Lakkaraju, A., Strub, K., Trono, D., 2008. Character-
ization of APOBEC3G binding to 7SL RNA. Retrovirology 5, 54.
Beale, R.C., Petersen-Mahrt, S.K., Watt, I.N., Harris, R.S., Rada, C., Neuberger, M.S.,
2004. Comparison of the differential context-dependence of DNA deamination
by APOBEC enzymes: correlation with mutation spectra in vivo. J. Mol. Biol.337,
585–596.
Bélanger, K., Savoie, M., Aydin, H., Renner, T.M., Montazeri, Z., Langlois, M.A., 2014.
Deamination intensity proﬁling of human APOBEC3 protein activity along the
near full-length genomes of HIV-1 and MoMLV by HyperHRM analysis. Virology
448, 168–175.
Bélanger, K., Savoie, M., Rosales Gerpe, M.C., Couture, J.F., Langlois, M.A., 2013.
Binding of RNA by APOBEC3G controls deamination-independent restriction of
retroviruses. Nucleic Acids Res. 41, 7438–7452.
Bishop, K.N., Holmes, R.K., Malim, M.H., 2006. Antiviral potency of APOBEC proteins
does not correlate with cytidine deamination. J. Virol. 80, 8450–8458.
K. Bélanger, M.-A. Langlois / Virology 483 (2015) 141–148 147
Bishop, K.N., Verma, M., Kim, E.Y., Wolinsky, S.M., Malim, M.H., 2008. APOBEC3G
inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog. 4, e1000231.
Bohn, M.F., Shandilya, S.M., Albin, J.S., Kouno, T., Anderson, B.D., McDougle, R.M.,
Carpenter, M.A., Rathore, A., Evans, L., Davis, A.N., Zhang, J., Lu, Y., Somasun-
daran, M., Matsuo, H., Harris, R.S., Schiffer, C.A., 2013. Crystal structure of the
DNA cytosine deaminase APOBEC3F: the catalytically active and HIV-1 Vif-
binding domain. Structure 21, 1042–1050.
Bulliard, Y., Turelli, P., Rohrig, U.F., Zoete, V., Mangeat, B., Michielin, O., Trono, D.,
2009. Functional analysis and structural modeling of human APOBEC3G reveal
the role of evolutionarily conserved elements in the inhibition of human
immunodeﬁciency virus type 1 infection and Alu transposition. J. Virol. 83,
12611–12621.
Byeon, I.J., Ahn, J., Mitra, M., Byeon, C.H., Hercik, K., Hritz, J., Charlton, L.M., Levin, J.G.,
Gronenborn, A.M., 2013. NMR structure of human restriction factor APOBEC3A
reveals substrate binding and enzyme speciﬁcity. Nat. Commun. 4, 1890.
Carpenter, M.A., Rajagurubandara, E., Wijesinghe, P., Bhagwat, A.S., 2010. Determi-
nants of sequence-speciﬁcity within human AID and APOBEC3G. DNA Repair9,
579–587.
Chen, K.M., Harjes, E., Gross, P.J., Fahmy, A., Lu, Y., Shindo, K., Harris, R.S., Matsuo, H.,
2008. Structure of the DNA deaminase domain of the HIV-1 restriction factor
APOBEC3G. Nature 452, 116–119.
Chiu, Y.L., Soros, V.B., Kreisberg, J.F., Stopak, K., Yonemoto, W., Greene, W.C., 2005.
Cellular APOBEC3G restricts HIV-1 infection in resting CD4þT cells. Nature 435,
108–114.
Dang, Y., Wang, X., Esselman, W.J., Zheng, Y.H., 2006. Identiﬁcation of APOBEC3DE
as another antiretroviral factor from the human APOBEC family. J. Virol. 80,
10522–10533.
Desimmie, B.A., Delviks-Frankenberrry, K.A., Burdick, R.C., Qi, D., Izumi, T., Pathak, V.K.,
2014. Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. J.
Mol. Biol.426, 1220–1245.
Doehle, B.P., Schafer, A., Cullen, B.R., 2005. Human APOBEC3B is a potent inhibitor
of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 339, 281–288.
Gallois-Montbrun, S., Kramer, B., Swanson, C.M., Byers, H., Lynham, S., Ward, M.,
Malim, M.H., 2007. Antiviral protein APOBEC3G localizes to ribonucleoprotein
complexes found in P bodies and stress granules. J. Virol. 81, 2165–2178.
Grandgenett, D.P., Goodarzi, G., 1994. Folding of the multidomain human immu-
nodeﬁciency virus type-I integrase. Protein Sci.: Publ. Protein Soc. 3, 888–897.
Guo, F., Cen, S., Niu, M., Yang, Y., Gorelick, R.J., Kleiman, L., 2007. The interaction of
APOBEC3G with human immunodeﬁciency virus type 1 nucleocapsid inhibits
tRNA3Lys annealing to viral RNA. J. Virol. 81, 11322–11331.
Hache, G., Liddament, M.T., Harris, R.S., 2005. The retroviral hypermutation
speciﬁcity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA
cytosine deaminase domain. J. Biol. Chem. 280, 10920–10924.
Harris, R.S., Bishop, K.N., Sheehy, A.M., Craig, H.M., Petersen-Mahrt, S.K., Watt, I.N.,
Neuberger, M.S., Malim, M.H., 2003. DNA deamination mediates innate immu-
nity to retroviral infection. Cell 113, 803–809.
Harris, R.S., Dudley, J.P., 2015. APOBECs and virus restriction. Virology 479–480,
131–145.
Harris, R.S., Petersen-Mahrt, S.K., Neuberger, M.S., 2002. RNA editing enzyme
APOBEC1 and some of its homologs can act as DNA mutators. Mol. Cell. 10,
1247–1253.
Huthoff, H., Autore, F., Gallois-Montbrun, S., Fraternali, F., Malim, M.H., 2009. RNA-
dependent oligomerization of APOBEC3G is required for restriction of HIV-1.
PLoS Pathog. 5, e1000330.
Huthoff, H., Malim, M.H., 2007. Identiﬁcation of amino acid residues in APOBEC3G
required for regulation by human immunodeﬁciency virus type 1 Vif and Virion
encapsidation. J. Virol. 81, 3807–3815.
Iwatani, Y., Chan, D.S., Wang, F., Maynard, K.S., Sugiura, W., Gronenborn, A.M.,
Rouzina, I., Williams, M.C., Musier-Forsyth, K., Levin, J.G., 2007. Deaminase-
independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic
Acids Res. 35, 7096–7108.
Iwatani, Y., Takeuchi, H., Strebel, K., Levin, J.G., 2006. Biochemical activities of highly
puriﬁed, catalytically active human APOBEC3G: correlation with antiviral effect.
J. Virol. 80, 5992–6002.
Jarmuz, A., Chester, A., Bayliss, J., Gisbourne, J., Dunham, I., Scott, J., Navaratnam, N.,
2002. An anthropoid-speciﬁc locus of orphan C to U RNA-editing enzymes on
chromosome 22. Genomics 79, 285–296.
Khan, M.A., Goila-Gaur, R., Opi, S., Miyagi, E., Takeuchi, H., Kao, S., Strebel, K., 2007.
Analysis of the contribution of cellular and viral RNA to the packaging of
APOBEC3G into HIV-1 virions. Retrovirology 4, 48.
Kitamura, S., Ode, H., Nakashima, M., Imahashi, M., Naganawa, Y., Kurosawa, T.,
Yokomaku, Y., Yamane, T., Watanabe, N., Suzuki, A., Sugiura, W., Iwatani, Y.,
2012. The APOBEC3C crystal structure and the interface for HIV-1 Vif binding.
Nat. Struct. Mol. Biol. 19, 1005–1010.
Kohli, R.M., Abrams, S.R., Gajula, K.S., Maul, R.W., Gearhart, P.J., Stivers, J.T., 2009. A
portable hot spot recognition loop transfers sequence preferences from
APOBEC family members to activation-induced cytidine deaminase. J. Biol.
Chem. 284, 22898–22904.
Kohli, R.M., Maul, R.W., Guminski, A.F., McClure, R.L., Gajula, K.S., Saribasak, H.,
McMahon, M.A., Siliciano, R.F., Gearhart, P.J., Stivers, J.T., 2010. Local sequence
targeting in the AID/APOBEC family differentially impacts retroviral restriction
and antibody diversiﬁcation. J. Biol. Chem. 285, 40956–40964.
Kozak, S.L., Marin, M., Rose, K.M., Bystrom, C., Kabat, D., 2006. The anti-HIV-1
editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle
between polysomes and stress granules. J. Biol. Chem. 281, 29105–29119.
Langlois, M., Beale, R., Conticello, S., Neuberger, M., 2005. Mutational comparison of
the single-domained APOBEC3C and double-domained APOBEC3F/G anti-
retroviral cytidine deaminases provides insight into their DNA target site
speciﬁcities. Nucleic Acids Res. 33, 1913–1923.
LaRue, R.S., Andresdottir, V., Blanchard, Y., Conticello, S.G., Derse, D., Emerman, M.,
Greene, W.C., Jonsson, S.R., Landau, N.R., Lochelt, M., Malik, H.S., Malim, M.H., Munk,
C., O’Brien, S.J., Pathak, V.K., Strebel, K., Wain-Hobson, S., Yu, X.F., Yuhki, N., Harris, R.
S., 2009. Guidelines for naming nonprimate APOBEC3 genes and proteins. J. Virol.
83, 494–497.
Lavens, D., Peelman, F., Van der Heyden, J., Uyttendaele, I., Catteeuw, D., Verhee, A.,
Van Schoubroeck, B., Kurth, J., Hallenberger, S., Clayton, R., Tavernier, J., 2010.
Deﬁnition of the interacting interfaces of Apobec3G and HIV-1 Vif using
MAPPIT mutagenesis analysis. Nucleic Acids Res. 38, 1902–1912.
Lecossier, D., Bouchonnet, F., Clavel, F., Hance, A.J., 2003. Hypermutation of HIV-1
DNA in the absence of the Vif protein. Science 300, 1112.
Li, X.Y., Guo, F., Zhang, L., Kleiman, L., Cen, S., 2007. APOBEC3G inhibits DNA strand
transfer during HIV-1 reverse transcription. J. Biol. Chem. 282, 32065–32074.
Liddament, M.T., Brown, W.L., Schumacher, A.J., Harris, R.S., 2004. APOBEC3F
properties and hypermutation preferences indicate activity against HIV-1
in vivo. Curr. Biol.: CB 14, 1385–1391.
Logue, E.C., Bloch, N., Dhuey, E., Zhang, R., Cao, P., Herate, C., Chauveau, L., Hubbard,
S.R., Landau, N.R., 2014. A DNA sequence recognition loop on APOBEC3A
controls substrate speciﬁcity. PloS One 9, e97062.
Lu, X., Zhang, T., Xu, Z., Liu, S., Zhao, B., Lan, W., Wang, C., Ding, J., Cao, C., 2015.
Crystal structure of DNA cytidine deaminase abobec3g catalytic deamination
domain suggests a binding mode of full-length enzyme to single-stranded DNA.
J. Biol. Chem. 290, 4010–4021.
Luo, K., Wang, T., Liu, B., Tian, C., Xiao, Z., Kappes, J., Yu, X.F., 2007. Cytidine
deaminases APOBEC3G and APOBEC3F interact with human immunodeﬁciency
virus type 1 integrase and inhibit proviral DNA formation. J. Virol. 81,
7238–7248.
Mangeat, B., Turelli, P., Liao, S., Trono, D., 2004. A single amino acid determinant
governs the species-speciﬁc sensitivity of APOBEC3G to Vif action. J. Biol. Chem.
279, 14481–14483.
Mariani, R., Chen, D., Schrofelbauer, B., Navarro, F., Konig, R., Bollman, B., Munk, C.,
Nymark-McMahon, H., Landau, N.R., 2003. Species-speciﬁc exclusion of APO-
BEC3G from HIV-1 virions by Vif. Cell 114, 21–31.
Mbisa, J.L., Bu, W., Pathak, V.K., 2010. APOBEC3F and APOBEC3G inhibit HIV-1 DNA
integration by different mechanisms. J. Virol. 84, 5250–5259.
Navarro, F., Bollman, B., Chen, H., Konig, R., Yu, Q., Chiles, K., Landau, N.R., 2005.
Complementary function of the two catalytic domains of APOBEC3G. Virology
333, 374–386.
Neuberger, M.S., Harris, R.S., Di Noia, J., Petersen-Mahrt, S.K., 2003. Immunity
through DNA deamination. Trends Biochem. Sci. 28, 305–312.
Newman, E.N., Holmes, R.K., Craig, H.M., Klein, K.C., Lingappa, J.R., Malim, M.H.,
Sheehy, A.M., 2005. Antiviral function of APOBEC3G can be dissociated from
cytidine deaminase activity. Curr. Biol.: CB 15, 166–170.
OhAinle, M., Kerns, J.A., Malik, H.S., Emerman, M., 2006. Adaptive evolution and
antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H.
J. Virol. 80, 3853–3862.
Rathore, A., Carpenter, M.A., Demir, O., Ikeda, T., Li, M., Shaban, N.M., Law, E.K.,
Anokhin, D., Brown, W.L., Amaro, R.E., Harris, R.S., 2013. The local dinucleotide
preference of APOBEC3G can be altered from 50-CC to 50-TC by a single amino
acid substitution. J. Mol. Biol. 425, 4442–4454.
Schrofelbauer, B., Chen, D., Landau, N.R., 2004. A single amino acid of APOBEC3G
controls its species-speciﬁc interaction with virion infectivity factor (Vif). Proc.
Natl. Acad. Sci. USA 101, 3927–3932.
Shindo, K., Li, M., Gross, P.J., Brown, W.L., Harjes, E., Lu, Y., Matsuo, H., Harris, R.S.,
2012. A comparison of two single-stranded DNA binding models by mutational
analysis of APOBEC3G. Biology 1, 260–276.
Siu, K.K., Sultana, A., Azimi, F.C., Lee, J.E., 2013. Structural determinants of HIV-1 Vif
susceptibility and DNA binding in APOBEC3F. Nat. Commun. 4, 2593.
Suspene, R., Henry, M., Guillot, S., Wain-Hobson, S., Vartanian, J.P., 2005. Recovery
of APOBEC3-edited human immunodeﬁciency virus G-4A hypermutants by
differential DNA denaturation PCR. J. Gen. Virol. 86, 125–129.
Suspene, R., Sommer, P., Henry, M., Ferris, S., Guetard, D., Pochet, S., Chester, A.,
Navaratnam, N., Wain-Hobson, S., Vartanian, J.P., 2004. APOBEC3G is a single-
stranded DNA cytidine deaminase and functions independently of HIV reverse
transcriptase. Nucleic Acids Res. 32, 2421–2429.
Szilvay, A.M., Nornes, S., Haugan, I.R., Olsen, L., Prasad, V.R., Endresen, C., Goff, S.P.,
Helland, D.E., 1992. Epitope mapping of HIV-1 reverse transcriptase with
monoclonal antibodies that inhibit polymerase and RNase H activities. J. Acquir.
Immune Deﬁc. Syndr. 5, 647–657.
Wang, M., Rada, C., Neuberger, M.S., 2010. Altering the spectrum of immunoglo-
bulin V gene somatic hypermutation by modifying the active site of AID. J. Exp.
Med. 207, 141–153.
Wang, X., Ao, Z., Chen, L., Kobinger, G., Peng, J., Yao, X., 2012. The cellular antiviral
protein APOBEC3G interacts with HIV-1 reverse transcriptase and inhibits its
function during viral replication. J. Virol. 86, 3777–3786.
Wichroski, M.J., Robb, G.B., Rana, T.M., 2006. Human retroviral host restriction
factors APOBEC3G and APOBEC3F localize to mRNA processing bodies. PLoS
Pathog. 2, e41.
Yu, Q., Konig, R., Pillai, S., Chiles, K., Kearney, M., Palmer, S., Richman, D., Cofﬁn, J.M.,
Landau, N.R., 2004. Single-strand speciﬁcity of APOBEC3G accounts for minus-
strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 11, 435–442.
K. Bélanger, M.-A. Langlois / Virology 483 (2015) 141–148148
